Skip to content

EEG-Based Efficacy Evaluation of Lecanemab Treatment in Alzheimer's Disease

EEG-Based Efficacy Evaluation of Lecanemab Treatment in Alzheimer's Disease

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500106454
Enrollment
Unknown
Registered
2025-07-24
Start date
2025-07-25
Completion date
Unknown
Last updated
2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Alzheimer's diasease

Interventions

Observation Group:None

Sponsors

Shenzhen people's hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
50 Years to 89 Years

Inclusion criteria

Inclusion criteria: 1. Presence of memory decline. 2. Age between 50 and 90 years. 3. Right-handedness. 4. Diagnosis of Alzheimer's disease (AD)-related mild cognitive impairment (MCI) or mild AD dementia according to the criteria established by the National Institute on Aging and the Alzheimer's Association (NIA-AA). 5. Amyloid positivity confirmed by PET imaging or cerebrospinal fluid (CSF) Aß1-42 measurements. 6. Objective impairment in episodic memory, evidenced by a delayed recall score on the Auditory Verbal Learning Test (AVLT) that is more than 1.5 standard deviations below the age-adjusted norm. 7. Montreal Cognitive Assessment (MoCA) score 22. 8. Provision of written informed consent.

Exclusion criteria

Exclusion criteria: 1. Presence of major psychiatric disorders that can lead to cognitive decline (e.g., depression, severe anxiety, significant sleep disorders, schizophrenia), or scores indicating severe anxiety (Hamilton Anxiety Rating Scale \[HAMA] >= 21), or scores suggesting mild to moderate depression (Hamilton Depression Rating Scale \[HAMD] >= 20), or poor sleep quality (Pittsburgh Sleep Quality Index \[PSQI] > 15). 2. Presence of other significant neurological disorders that can cause cognitive decline. 3. Presence of other pathological factors leading to cognitive decline. 4. Cranial MRI showing cerebral infarction, white matter lesions with a Fazekas scale score >= 2, space-occupying lesions, or other significant abnormal signals. 5. Hachinski Ischemic Score > 4. 6. Use of antidepressants, hypnotics, antiepileptic drugs, or similar medications within 4 weeks prior to enrollment. 7. Severe cognitive impairment, language disorders, or inability to cooperate with assessments and examinations.

Design outcomes

Primary

MeasureTime frame
ADS-Cog;

Secondary

MeasureTime frame
rsEEG;MOCA;MMSE;CDR;

Countries

China

Contacts

Public ContactZhou Zhifan

Shenzhen people's hospital

zhouzhifan1005@163.com+86 189 2463 3693

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026